Money Is Moving

Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Public market insider buying at Knight Therapeutics (T:GUD)

Updated Tuesday Sep 19, 2023 02:19 AM EDT

Sime Armoyan, a 10% Holder, acquired 34,700 Common Shares on a control or direction basis for registered holder Armco Alberta Inc. at prices ranging from $4.384 to $4.400 between September 13th, 2023 and September 15th, 2023. This represents a $152,246 investment into the company's shares and an account share holdings change of 0.3%.

Knight Therapeutics is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company is engaged in the development, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It also finances other life sciences companies, invests in venture capital funds and develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's products include EXELON, BIJUVA, IMVEXXY, IBSRELA, TRELSTAR Prostate, TRELSTAR Endometriosis, Nerlynx, Nerlynx Patient Checklist, Nerlynx Prescriber Checklist, Burinex, Probuphine, Movantik and Neuragen. It owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. The Company's subsidiary includes Knight Therapeutics International S.A., which develops pharmaceuticals, including those used to treat neglected tropical diseases and rare pediatric diseases.

INK Edge Outlook

6 months ago
1 year ago
Mostly Sunny
Mostly Sunny
The INK Edge Outlook is a quantitative process that ranks a stock based on our V.I.P. criteria.
View outlooks on all Canadian listed stocks at
Two-week free trial for first time users.
Go to Knight Therapeutics Inc. (GUD)'s company page

Comment On!

Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to (via Easy Blurb).

Comment On!

No Comments


Search (past week) for $GUD.CA

  • No tweets found